Loading...
Market
Will Recursion Pharmaceuticals announce Phase 3 trial for REC-994 by end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Recursion Pharmaceuticals
Story
Recursion's First-in-Disease Drug REC-994 Meets Safety Endpoint, Efficacy Mixed in Phase 2 Study
Sep 3, 2024, 12:12 PM
Recursion Pharmaceuticals has announced the Phase 2 data for REC-994, its first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The AI-derived drug candidate met its primary endpoint of safety and tolerability in the mid-stage study. However, the efficacy results were mixed, with magnetic resonance imaging-based secondary endpoints showing a trend towards reduced lesion volume but not achieving significant efficacy. While the topline results are positive, they may not fully satisfy investors closely monitoring the AI drug developer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Yes • 50%
No • 50%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%